Enalapril maleate (MK421), a new inhibitor of angiotensin converting enzyme, in single daily
doses of 1.25-40 mg was assessed in five patients with hypertension and renal artery …

The converting enzyme inhibitor, enalapril, was given to 20 hypertensive patients with renal
artery stenosis in a single daily dose of 10-40 mg. Enalapril effectively controlled …

The converting enzyme inhibitor enalapril, in single daily doses of 10-40 mg, was given to
20 hypertensive patients with renal artery stenosis. The blood pressure fall six hours after …

The renal effects of the new angiotensin converting enzyme inhibitor enalapril (MK-421) and
of its active metabolite MK-422, were investigated in patients with essential hypertension …

The converting enzyme inhibitor enalapril, in single daily doses of 10 to 40 mg, was given to
20 hypertensive patients with renal artery stenosis. The decrease in blood pressure six …

A non-sulfhydryl-containing inhibitor of angiotensin-converting enzyme (MK421) was given
as a single dose in a randomised double-blind cross-over trial using 20 mg and 5 mg of MK …

Thirteen patients were entered into a protocol to assess the safety and efficacy of enalapril
(MK 421), 5 to 20 mg bid, and hydrochlorothiazide, 50 to 100 mg daily, for the treatment of …

The new angiotensin converting enzyme inhibitor enalapril (MK421), was given in a single
daily dose of 20 mg to 53 patients with uncomplicated essential hypertension. Its effects …

To assess the effect of MK-421 (enalapril) we treated six hospitalized hypertensive patients
receiving constant sodium intake with incremental doses of this new angiotensin-converting …

The antihypertensive, hemodynamic, and humoral effects of the new converting-enzyme
inhibitor enalapril (MK-421) were assessed by sequential studies during 3 months of …